Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company is headquartered in New York, New York.

Neurogene Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurogene (NGNE) and Lyell Immunopharma (LYEL) with ...

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lyell Immunopharma (LYEL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and M...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NGNE	$31.53	+2.40%	308.96K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NGNE	$31.53	+2.4%	308.96K
3
4
5
6

NGNE

NGNE

Recent News for NGNE

Get Neurogene Inc. Data in Excel

Get Neurogene Inc. Data in Excel